Business & Regulation

The 21st Century Cures Act is passed through US Congress – and includes big plans for the FDA.

A storm around drug pricing is building for 2017, but it shouldn’t overshadow the great and good.

Open innovation done right can help overcome funding challenges and accelerate discovery

The FDA consults stakeholders over plans to loosen restrictions on off-label drug marketing

Evidence suggests that price controls could hamper innovation and negatively affect patient health outcomes.

Sitting Down With Steve Turley, Managing Director for the British and Irish Isles, UCB.

Patients don’t always read drug risk information – even when they say they do

A podcast series lets listeners eavesdrop on a conversation between scientists in a bar

What impact will Brexit, a new US President, and a flood of new technologies have on the industry?

Steve Keen talks to us about Trump, China, free trade and globalization